| Literature DB >> 27751757 |
Fernanda Sales Luiz Vianna1, Thayne Woycinck Kowalski2, Luciana Tovo-Rodrigues3, Alice Tagliani-Ribeiro4, Bibiane Armiliato Godoy4, Lucas Rosa Fraga2, Maria Teresa Vieira Sanseverino5, Mara Helena Hutz4, Lavínia Schuler-Faccini6.
Abstract
Thalidomide causes Thalidomide Embryopathy (TE), but is largely used to treat several conditions. Investigations with Cereblon, a thalidomide target protein encoded by CRBN gene, have helped to understand thalidomide therapeutic and teratogenic properties. We sequenced CRBN-thalidomide binding region in 38 TE individuals and 136 Brazilians without congenital anomalies, and performed in silico analyses. Eight variants were identified, seven intronic and one in 3'UTR. TE individuals had rare variants in higher frequency than the non-affected group (p=0.04). The genotype rs1620675 CC was related to neurological anomalies in TE individuals (p=0.004). Bioinformatics analysis suggested this genotype leads to potential alterations in splicing sites and binding to transcription factors. Comparison of the Cereblon-thalidomide binding domains in mammals demonstrated that CRBN is highly conserved across species. All the variants require evaluation in functional assays in order to understand their role in Cereblon-thalidomide binding and complex interactions that lead to TE. Copyright ÂEntities:
Keywords: CRBN; Cereblon; Teratogenesis; Thalidomide; Thalidomide embryopathy
Mesh:
Substances:
Year: 2016 PMID: 27751757 DOI: 10.1016/j.reprotox.2016.10.003
Source DB: PubMed Journal: Reprod Toxicol ISSN: 0890-6238 Impact factor: 3.143